Photodynamic Therapy Mediated by Nontoxic Core–Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer

An effective, nontoxic, tumor-specific immunotherapy is the ultimate goal in the battle against cancer, especially the metastatic disease. Checkpoint blockade-based immunotherapies have been shown to be extraordinarily effective but benefit only the minority of patients whose tumors have been pre-infiltrated by T cells. Here, we show that Zn-pyrophosphate (ZnP) nanoparticles loaded with the photosensitizer pyrolipid (ZnP@pyro) can kill tumor cells upon irradiation with light directly by inducing apoptosis and/or necrosis and indirectly by disrupting tumor vasculature and increasing tumor immunogenicity. Furthermore, immunogenic ZnP@pyro photodynamic therapy (PDT) treatment sensitizes tumors to checkpoint inhibition mediated by a PD-L1 antibody, not only eradicating the primary 4T1 breast tumor but also significantly preventing metastasis to the lung. The abscopal effects on both 4T1 and TUBO bilateral syngeneic mouse models further demonstrate that ZnP@pyro PDT treatment combined with anti-PD-L1 results in the eradication of light-irradiated primary tumors and the complete inhibition of untreated distant tumors by generating a systemic tumor-specific cytotoxic T cell response. These findings indicate that nanoparticle-mediated PDT can potentiate the systemic efficacy of checkpoint blockade immunotherapies by activating the innate and adaptive immune systems in tumor microenvironment

Chlorin-Based Nanoscale Metal–Organic Framework Systemically Rejects Colorectal Cancers via Synergistic Photodynamic Therapy and Checkpoint Blockade Immunotherapy

Photodynamic therapy (PDT) can destroy local tumors and minimize normal tissue damage, but is ineffective at eliminating metastases. Checkpoint blockade immunotherapy has enjoyed recent success in the clinic, but only elicits limited rates of systemic antitumor response for most cancers due to insufficient activation of the host immune system. Here we describe a treatment strategy that combines PDT by a new chlorin-based nanoscale metal–organic framework (nMOF), TBC-Hf, and a small-molecule immunotherapy agent that inhibits indoleamine 2,3-dioxygenase (IDO), encapsulated in the nMOF channels to induce systemic antitumor immunity. The synergistic combination therapy achieved effective local and distant tumor rejection in colorectal cancer models. We detected increased T cell infiltration in the tumor microenvironment after activation of the immune system with the combination of IDO inhibition by the small-molecule immunotherapy agent and immunogenic cell death induced by PDT. We also elucidated the underlying immunological mechanisms and revealed compensatory roles of neutrophils and B cells in presenting tumor-associated antigens to T cells in this combination therapy. We believe that nMOF-enabled PDT has the potential to significantly enhance checkpoint blockade cancer immunotherapy, affording clinical benefits for the treatment of many difficult-to-treat cancers

TLR3 Signaling in Macrophages Is Indispensable for the Protective Immunity of Invariant Natural Killer T Cells against Enterovirus 71 Infection

<div><p>Enterovirus 71 (EV71) is the most virulent pathogen among enteroviruses that cause hand, foot and mouth disease in children but rarely in adults. The mechanisms that determine the age-dependent susceptibility remain largely unclear. Here, we found that the paucity of invariant natural killer T (iNKT) cells together with immaturity of the immune system was related to the susceptibility of neonatal mice to EV71 infection. iNKT cells were crucial antiviral effector cells to protect young mice from EV71 infection before their adaptive immune systems were fully mature. EV71 infection led to activation of iNKT cells depending on signaling through TLR3 but not other TLRs. Surprisingly, iNKT cell activation during EV71 infection required TLR3 signaling in macrophages, but not in dendritic cells (DCs). Mechanistically, interleukin (IL)-12 and endogenous CD1d-restricted antigens were both required for full activation of iNKT cells. Furthermore, CD1d-deficiency led to dramatically increased viral loads in central nervous system and more severe disease in EV71-infected mice. Altogether, our results suggest that iNKT cells may be involved in controlling EV71 infection in children when their adaptive immune systems are not fully developed, and also imply that iNKT cells might be an intervention target for treating EV71-infected patients.</p></div

IL-12 and endogenous CD1d antigens are both required for full iNKT cell activation in EV71 infection.

<p>(A) EV71M-infected or-uninfected WT macrophages (Mock) were co-cultured with purified iNKT cells in the presence of neutralizing anti-CD1d (αCD1d), isotype control antibodies (Iso) or medium alone (M). (B) EV71M-infected or –uninfected WT or CD1d-deficient (CD1d^-/-) macrophages were co-cultured with purified iNKT cells. (C) EV71-infected WT macrophages were co-cultured with purified iNKT cells in the presence of the lipid synthesis inhibitor NB-DGJ or medium alone. (D) Seven-day-old WT or CD1d^-/- neonates (n = 3–5) were adoptively transferred with 5×10⁵ purified iNKT cells or saline control intraperitoneally and infected with 2×10⁵ PFU of EV71M. After 16 hours, splenocytes of saline (mock)-treated or EV71M-infected WT or CD1d^-/- mice were stained with TCRβ, CD1d tetramer, CD69 and DAPI. The CD69 MFI levels on iNKT cells are shown. (E) EV71M-infected WT macrophages were co-cultured with purified iNKT cells in the presence of neutralizing anti-IL-12, anti-IL-18 or isotype control antibodies. The IFN-γ concentrations in the 24-hour culture supernatants were quantified by ELISA. (F) The IL-12 (p70) concentrations in the supernatants of WT or TLR3^-/- macrophages infected with 10 MOIs of EV71M. All results represent the mean ± SD. NS, not significant; *, <i>P</i><0.05; **, <i>P</i><0.01. Data are representative of three (A, B, C, E, F) or two (D) independent experiments.</p

TLR3 is indispensable for iNKT cell activation in EV71 infection.

<p>(A) TLR3 signaling is required for IFN-γ production by EV71-infected splenocytes. Splenocytes from WT, TLR3^-/-, TLR7^-/- and MyD88^-/- mice (n = 3–5) were cultured with EV71M or mock for 24 hours, and IFN-γ production was quantified by ELISA. (B) TLR3 deficiency dramatically reduced the IFN-γ production of iNKT cells. Splenocytes from CD1d-deficient or WT C57BL/6 mice (n = 3) were infected with EV71M for 24 hours and then stained with TCRβ, CD1d tetramer and IFN-γ. Splenocytes were stimulated with PMA and ionomycin (PMA/I) or mock treated (mock), which served as positive and negative controls, respectively. IFN-γ-producing cells are shown among CD1d tetramer⁺ TCR⁺-gated cells. (C) iNKT cell activation in EV71 infection is dependent on TLR3 signaling. Macrophages from WT or TLR3^-/- mice were cultured in the presence of EV71M for 24 hours. After extensive washing, macrophages were co-cultured for 48 hours with purified iNKT cells from WT mice, and cytokine production was quantified by ELISA. (D) TLR3 signaling is required for <i>in vivo</i> activation of iNKT cells upon EV71M infection. Six-8 week-old WT or TLR3^-/- mice (n = 3–6) were injected with 1×10⁵ PFU of EV71M or saline intraperitoneally. After 16 hours, splenocytes of mock (PBS) or EV71M-infected WT or TLR3^-/- mice were stained with TCRβ, CD1d tetramer, CD69 and DAPI. The mean fluorescent intensity (MFI) of CD69 expression on iNKT cells is shown. NS, not significant; **, <i>P</i><0.01. (E) TLR3 triggering in macrophages activated iNKT cells. BMDCs or macrophages were cultured with medium alone or pI:C for 24 hours and then co-cultured with purified iNKT cells from WT mice for 48 hours. Cytokine production was quantified by ELISA. All results represent the mean values of cultures of 5 mice ± SD. *, <i>P</i><0.05. (F) The survival rates of 7-day-old wild-type (WT) mice and TLR3-deficient (TLR3^-/-) mice (n = 6, per group) after infection by 1×10⁶ PFU of EV71M. Data are representative of three (A, C, E, F) or two (B. D) independent experiments.</p

CD1d is essential for the protection of young mice from EV71 infection.

<p>Seven-day-old WT and CD1d^-/- mice were infected intraperitoneally with a lower dose (A, 2×10⁴ PFU) or higher dose (B, 2×10⁵ PFU) of EV71M. The clinical score (A) and survival (B, Kaplan-Meier curve) were monitored for the indicated period (n ≥ 10 per group). (C) Kaplan-Meier survival curves for 7-day-old WT and Jα18^-/- mice (n ≥ 5 per group) that were infected intraperitoneally with 2×10⁵ PFU of EV71M. The viral loads in each organ were examined by quantitative PCR on days 2 (D) and 4 (E) after the high dose of EV71M infection. Data are shown as the mean ± SD of three independent samples. NS, not significant; **, <i>P</i><0.01. Data are representative of two independent experiments.</p